Literature DB >> 11744725

Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.

Thomas J Podor1, Davindra Singh, Paul Chindemi, Denise M Foulon, Robert McKelvie, Jeffrey I Weitz, Richard Austin, Ghislain Boudreau, Richard Davies.   

Abstract

Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type plasminogen activator (t-PA), is found in plasma and platelets. PAI-1 circulates in complex with vitronectin (Vn), an interaction that stabilizes PAI-1 in its active conform. In this study, we examined the binding of platelet-derived Vn and PAI-1 to the surface of isolated platelets. Flow cytometry indicate that, like P-selectin, PAI-1, and Vn are found on the surface of thrombin- or calcium ionophore-activated platelets and platelet microparticles. The binding of PAI-1 to the activated platelet surface is Vn-dependent. Vn mediates the binding of PAI-1 to platelet surfaces through a high affinity (K(d) of 80 nm) binding interaction with the NH(2) terminus of vimentin, and this Vn-binding domain is expressed on the surface of activated platelets and platelet microparticles. Immunological and functional assays indicate that only -5% of the total PAI-1 in platelet releasates is functionally active, and it co-precipitates with Vn, and the vimentin-enriched cytoskeleton fraction of activated platelet debris. The remaining platelet PAI-1 is inactive, and does not associate with the cytoskeletal debris of activated platelets. Confocal microscopic analysis of platelet-rich plasma clots confirm the co-localization of PAI-1 with Vn and vimentin on the surface of activated platelets, and platelet microparticles. These findings suggest that platelet vimentin may regulate fibrinolysis in plasma and thrombi by binding platelet-derived Vn.PAI-1 complexes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744725     DOI: 10.1074/jbc.M109675200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Platelet microparticles and platelet adhesion: therapeutic implications for the prevention and treatment of stroke.

Authors:  Kiat T Tan; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels.

Authors:  Charles P Mercado; Fusun Kilic
Journal:  Mol Interv       Date:  2010-08

3.  The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes.

Authors:  Boryana Stamova; Bradley P Ander; Glen Jickling; Farah Hamade; Marc Durocher; Xinhua Zhan; Da Zhi Liu; Xiyuan Cheng; Heather Hull; Alan Yee; Kwan Ng; Natasha Shroff; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-13       Impact factor: 6.200

Review 4.  Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer.

Authors:  S I Brett; Y Kim; C N Biggs; J L Chin; H S Leong
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-12       Impact factor: 5.554

5.  A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemia.

Authors:  Trung C Nguyen; Francisca Gushiken; Juliana I Correa; Jing-Fei Dong; Swapan K Dasgupta; Perumal Thiagarajan; Miguel A Cruz
Journal:  Thromb Res       Date:  2015-03-03       Impact factor: 3.944

Review 6.  The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections.

Authors:  Amy E Bryant; Clifford R Bayer; Michael J Aldape; Dennis L Stevens
Journal:  Curr Opin Infect Dis       Date:  2015-06       Impact factor: 4.915

7.  Extracellular Vimentin/VWF (von Willebrand Factor) Interaction Contributes to VWF String Formation and Stroke Pathology.

Authors:  Titilope A Fasipe; Sung-Ha Hong; Qi Da; Christian Valladolid; Matthew T Lahey; Lisa M Richards; Andrew K Dunn; Miguel A Cruz; Sean P Marrelli
Journal:  Stroke       Date:  2018-10       Impact factor: 7.914

8.  Endocytic uptake pathways utilized by CPMV nanoparticles.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Mol Pharm       Date:  2012-09-20       Impact factor: 4.939

9.  Validation of the vitronectin knockout mouse as a model for studying myocardial infarction: Vitronectin appears to influence left ventricular remodelling following myocardial infarction.

Authors:  Gordon E Pate; Hubert P Walinski; Lubos Bohunek; Thomas J Podor
Journal:  Exp Clin Cardiol       Date:  2013

10.  Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis.

Authors:  Eduardo Ramacciotti; Angela E Hawley; Diana M Farris; Nicole E Ballard; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.